Amphastar Pharmaceuticals, Inc. Income (Loss) from Continuing Operations before Income Taxes, Domestic
Amphastar Pharmaceuticals, Inc. (AMPH) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of $128.95 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-02-26
- Amphastar Pharmaceuticals, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was $128.95M, a 33.93% decline from fiscal 2024.
- Amphastar Pharmaceuticals, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was $195.18M, a 7.29% increase from fiscal 2023.
- Amphastar Pharmaceuticals, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was $181.92M, a 43.02% increase from fiscal 2022.
- Amphastar Pharmaceuticals, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was $127.20M, a 47.51% increase from fiscal 2021.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month as first filed |
|---|---|---|
| 2025-12-31 | $128.95M 10-K · filed 2026-02-26 | |
| 2024-12-31 | $195.18M 10-K · filed 2026-02-26 | |
| 2023-12-31 | $181.92M 10-K · filed 2026-02-26 | |
| 2022-12-31 | $127.20M 10-K · filed 2025-03-03 | |
| 2021-12-31 | $86.24M 10-K · filed 2024-02-29 | |
| 2020-12-31 | $15.63M 10-K · filed 2023-03-01 | |
| 2019-12-31 | $77.09M 10-K · filed 2022-03-11 | |
| 2018-12-31 | $3.58M 10-K · filed 2021-03-15 | |
| 2017-12-31 | $6.89M 10-K · filed 2020-03-16 | $7.27M 10-K · filed 2018-03-14 |
| 2016-12-31 | $20.57M 10-K · filed 2019-03-15 | $20.89M 10-K · filed 2017-03-15 |
| 2015-12-31 | -$4.34M 10-K · filed 2018-03-14 | |
| 2014-12-31 | -$12.95M 10-K · filed 2017-03-15 | |
| 2013-12-31 | $20.12M 10-K · filed 2016-03-15 | |
| 2012-12-31 | $27.71M 10-K · filed 2015-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |